Kala firdhiso Large B-cell Lymphoma (DLBCL)

Bukaan-socodka, haweeney adkeysi leh oo ku dhow 80 sano jir, ayaa si geesinimo leh u wajahday ogaanshaha cudurka Diffuse Large B-cell Lymphoma (DLBCL), taasoo muujinaysa geesinimo cajiib ah oo ay kula dagaalamayso qaabkan halista ah ee kansarka.

In kasta oo ay da' weyn tahay, haddana waxay ku adkaysatay inay ka gudubto caqabadaha ka dhashay xaaladdeeda. Si kastaba ha ahaatee, lix bilood gudahood ka dib markii ay ku guulaysato cafiska daawaynta safka kowaad, waxay la kulantay soo noqoshada, iyada oo hoosta ka xariiqday dabeecadda qallafsan ee cudurkeeda. In kasta oo isku dayo badan lagu sameeyay daawaynta safka labaad iyo saddexaad, kansarkeedu waxa uu muujiyay iska caabin adag, taasoo caqabad weyn ku ah kooxdeeda caafimaadka.

Garashada degdegga ah ee xaaladdeeda, kooxda caafimaadku waxay bilaabeen raadinta si ay u sahamiyaan ikhtiyaarka daawaynta beddelka ah. Bukaan-socodka ayaa lagu diiwaan geliyay tijaabo caafimaad oo lagu baarayo CD19 + 22 CAR-T therapy cell, hab goynta ah oo ka faa'iidaysta unugyada T-ga hidde ahaan loo habeeyay si loo beegsado unugyada kansarka ee muujinaya antigens gaar ah.

Natiijadu ma ahayn wax aan caadi ahayn. Kaliya hal bil kadib faleebada CD19+22 unugyada CAR-T, bukaanku wuxuu helay cafis dhammaystiran. Natiijooyinkan la taaban karo kaliya kama joojin horumarka cudurkeeda laakiin waxay sidoo kale horseedday ciribtirka guuleysiga unugyada kansarka, taasoo calaamad u ah waqti muhiim u ah safarkeeda daaweynta.

Intii lagu jiray habka adag, kooxda caafimaadku waxay siiyeen taageero iyo daryeel aan leexleexad lahayn bukaanka. Laga soo bilaabo si dhow ula socoshada jawaabteeda daawaynta ilaa maaraynta dhacdooyinka xun, waxay hubiyeen in fayoobideeda ay sii ahaato mudnaanta koowaad.

Iyadoo dib u milicsanaysa waayo-aragnimadeeda, bukaanku wuxuu muujiyay mahadnaq qoto dheer oo ku saabsan daryeelka naxariista leh ee ay heshay. "Khibradda iyo khibradda kooxdayda caafimaadka waxay ahayd mid aad u wanaagsan," ayay tiri. "Habkooda gaarka ah ee daawaynta ayaa i siisay rajo markii aan aad ugu baahnaa."

Natiijada guusha leh ee CD19+22 daawaynta unugyada CAR-T ee lagu gaarayo cafiska dhameestiran waxay muujineysaa awooddeeda sida ikhtiyaar daawaynta rajo-gelinta ah ee bukaannada DLBCL ee dib-u-celinta. Kiiskan ayaa markhaati u ah awoodda daawaynta hal-abuurka leh iyo daawaynta shakhsi ahaaneed ee maaraynta kansarka kakan, gaar ahaan bukaannada waayeelka ah sida haweeneydan geesinimada leh.

Kahor & 1 bil kadib faleebo